美罗华联合CTOP方案治疗B细胞非霍奇金淋巴瘤35例临床分析

【作者】 王华庆； 韩霞； 刘贤明； 邱立华； 张会来； 钱正子； 李维； 李兰芳； 崔秀珍； 郝希山；

【机构】 天津医科大学肿瘤医院淋巴肿瘤科天津市肿瘤防治重点实验室；

【摘要】 目的评价美罗华联合CTOP(R-CTOP)方案治疗B细胞非霍奇金淋巴瘤的疗效及不良反应。方法经病理证实为CD20+的35例B细胞非霍奇金淋巴瘤患者均采用R-CTOP方案化疗,每2周期评价疗效及不良反应。结果33例患者可评价疗效,完全缓解(CR)17例(51.5%),部分缓解(PR)1 1例(33.3%),有效率(CR+PR)84.8%。23例初治患者中,CR13例(56.5%),PR 8例(34.8%),有效率(CR+PR)91.3%;1O例复发难治患者中,CR4例(40%),PR 3例(30%),有效率70%。不良反应主要为骨髓抑制(Ⅲ-Ⅳ度白细胞下降32.1%),心脏毒性和脱发较轻,其它不良反应经对症处理后均可耐受。结论R-CTOP方案治疗B细胞非霍奇金淋巴瘤有效率高且不良反应轻微,可作为治疗B细胞非霍奇金淋巴瘤特别是老年非霍奇金淋巴瘤的优先选择。更多还原

【Abstract】 Objective To evaluate the efficacy and toxicity of rituximab plus CTOP in patients with B cell non-Hodgkin’s lymphoma.Methods 35 patients with CD20 antigen positive were enrolled in the study.Rituximab plus CTOP were given to them and the efficacy and toxicity were evaluated every two cycles.Results 33 patients were evaluable for objective response.The complete response(CR)rate was 51.5%,the partical response(PR)rate was 33.3%,and the overall response was 84.8%.In the 23 de novo patients,the CR rate was 56.5%,the PR rate was 34.8%,and the OR rate was 91.3%.While in the 10 recurrent or relapsed patients,the CR rate was 40%,the PR rate was 30%,and the OR rate was 70%.The most frequent adverse events was myelosuppression(Ⅲ-Ⅳleukocyte account for 32.1%).Cardiotoxicity and alopecie were little and other side effects can be tolerated.Conclusions R-CTOP regimen is a highly effective and well-toleraed therapy and it should be the first choice in the treatment for B-NHL especially for old patients.更多还原